Wales first in the UK to launch groundbreaking type 1 diabetes trial

Wales has become the first UK nation to open recruitment for T1D-Plus—a major international clinical trial exploring innovative treatment strategies for adults newly diagnosed with type 1 diabetes (T1D). 

Led by the Centre for Trials Research at Cardiff University, this landmark study is a significant step forward in diabetes care and research in Wales. 

Opportunity for diabetes teams in Wales

This trial offers a unique opportunity for specialist diabetes services across Wales to contribute to cutting-edge research with the potential to reshape early intervention in type 1 diabetes. Early involvement and referral are key, as treatment is most effective in the first weeks after diagnosis.

Who can take part?

Eligible participants are:

• Aged 18 to 44
• Diagnosed with T1D within the last six weeks (42 days) from their first insulin dose
• Not previously treated with immunotherapy
• Able to attend follow-up appointments in Cardiff over 12 months

What’s involved?

Participants will:

• Visit the clinic every three months for one year
• Receive gradually increasing doses of Verapamil (up to 360 mg)
• Be allocated to a treatment arm involving either infusion, injection, or oral immune therapy

Led by experts in Wales

This trial is led by Professor Colin Dayan, Professor of Clinical Diabetes and Metabolism and Joint Research Office Director for Cardiff University and Cardiff and Vale Health Board and delivered through the INNODIA network.  

Professor Colin Dayan, Chief Investigator, said: “We know that the immune attack on insulin-producing cells is most active in the early weeks after diagnosis. 

“That’s why early referral is so important. By acting quickly, we can offer patients the chance to take part in research that could protect their remaining beta-cell function—and potentially change the course of their diabetes.” 

Strength in research

Dr Nicola Williams, National Director of Support and Delivery at Health and Care Research Wales, said: “Being the first country in the UK to open recruitment for the T1D-Plus trial highlights the strength of our research infrastructure and the dedication of our clinical teams across the country.” 

About the trial

T1D-Plus is a multi-centre, open-label trial testing whether the combination of a common blood pressure medication, Verapamil, with one of three immune therapies can better preserve insulin-producing beta cells compared to Verapamil alone. If successful, the approach could lead to improved blood glucose control, reduced insulin needs, and fewer long-term complications.

For more information or to refer patients, please contact Alex (Howella4@cardiff.ac.uk) or Shinto (joses8@cardiff.ac.uk), or visit www.type1diabetesresearch.org.uk